Akero Therapeutics Inc (AKRO) — Strategic Asset Allocation Index
Akero Therapeutics Inc (AKRO) has a Strategic Asset Allocation Index of 26.2% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $250.49 Million) total $250.49 Million, measured against net assets of $957.64 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See AKRO equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Akero Therapeutics Inc Strategic Asset Allocation Index (2020–2024)
This chart shows how Akero Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the index stands at 26.2%, representing strategic assets of $250.49 Million against net assets of $957.64 Million USD. For live market cap and overall valuation, see AKRO stock market capitalisation.
Annual Strategic Asset Allocation Index for Akero Therapeutics Inc (2020–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Akero Therapeutics Inc from 2020 to 2024, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See what is Akero Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 7.3% | $54.75 Million | $- | $54.75 Million | $750.11 Million | ▲ +3.7 pp |
| 2023 | 3.6% | $19.28 Million | $- | $19.28 Million | $535.31 Million | ▲ +3.6 pp |
| 2022 | 0.0% | $47.00K | $47.00K | $0.00 | $326.56 Million | ▼ 0.0 pp |
| 2021 | 0.1% | $90.00K | $90.00K | $- | $169.11 Million | ▼ -0.6 pp |
| 2020 | 0.7% | $1.79 Million | $1.79 Million | $- | $258.71 Million | — |